Tongling Jieya Biologic Technology Co. Ltd.
Tongling Jieya Biologic Technology Co., Ltd. engages in the research and development, production, and sales of wet wipe products in China. It offers baby, adult functional, antibacterial and disinfection, household clearing, medical care, pet cleaning wipes, wet toilet papers. The company also provides beauty care products, such as emollient water, Lotion, Cream, Essence, Membranes, clean, Body S… Read more
Tongling Jieya Biologic Technology Co. Ltd. (301108) - Total Assets
Latest total assets as of June 2025: CN¥2.19 Billion CNY
Based on the latest financial reports, Tongling Jieya Biologic Technology Co. Ltd. (301108) holds total assets worth CN¥2.19 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tongling Jieya Biologic Technology Co. Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Tongling Jieya Biologic Technology Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tongling Jieya Biologic Technology Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Tongling Jieya Biologic Technology Co. Ltd.'s total assets of CN¥2.19 Billion consist of 82.8% current assets and 17.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.4% |
| Accounts Receivable | CN¥135.76 Million | 6.5% |
| Inventory | CN¥77.19 Million | 3.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥34.45 Million | 1.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Tongling Jieya Biologic Technology Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tongling Jieya Biologic Technology Co. Ltd.'s current assets represent 82.8% of total assets in 2024, an increase from 64.0% in 2019.
- Cash Position: Cash and equivalents constituted 19.4% of total assets in 2024, down from 34.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 7.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 6.5% of total assets.
Tongling Jieya Biologic Technology Co. Ltd. Competitors by Total Assets
Key competitors of Tongling Jieya Biologic Technology Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
China | CN¥3.66 Billion |
|
Taiyen Biotech Co Ltd
TW:1737
|
Taiwan | NT$8.26 Billion |
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
China | CN¥2.20 Billion |
|
Hunan Resun Co Ltd
SHE:001218
|
China | CN¥3.08 Billion |
|
Dencare (Chongqing) Oral Care Co. Ltd. A
SHE:001328
|
China | CN¥1.90 Billion |
|
Qingdao Kingking Applied Chemistry Co Ltd
SHE:002094
|
China | CN¥3.19 Billion |
|
C&S Paper Co Ltd
SHE:002511
|
China | CN¥9.17 Billion |
|
Anhui Deli Household Glass Co Ltd
SHE:002571
|
China | CN¥3.08 Billion |
Tongling Jieya Biologic Technology Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tongling Jieya Biologic Technology Co. Ltd. generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Tongling Jieya Biologic Technology Co. Ltd. generates $ 0.94 in net profit.
Tongling Jieya Biologic Technology Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.14 | 6.80 | 6.55 |
| Quick Ratio | 5.73 | 6.53 | 6.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.36 Billion | CN¥ 1.44 Billion | CN¥ 1.51 Billion |
Tongling Jieya Biologic Technology Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Tongling Jieya Biologic Technology Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.15 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -3.2% |
| Total Assets | CN¥2.08 Billion |
| Market Capitalization | $148.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tongling Jieya Biologic Technology Co. Ltd.'s assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Tongling Jieya Biologic Technology Co. Ltd.'s assets decreased by 3.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Tongling Jieya Biologic Technology Co. Ltd. (2019–2024)
The table below shows the annual total assets of Tongling Jieya Biologic Technology Co. Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.08 Billion | -3.17% |
| 2023-12-31 | CN¥2.15 Billion | +3.96% |
| 2022-12-31 | CN¥2.07 Billion | +0.70% |
| 2021-12-31 | CN¥2.05 Billion | +134.64% |
| 2020-12-31 | CN¥874.76 Million | +121.80% |
| 2019-12-31 | CN¥394.39 Million | -- |